The combination of the antibody amivantamab and lazertinib, a drug targeting EGFR, shows better clinical benefits compared to standard treatment in patients with advanced or metastatic non-small cell lung cancer with EGFR gene mutations who also present one of these poor prognostic markers: brain and/or liver metastases, p53 gene co-mutations, or the presence of circulating tumor DNA. Dr. Enriqueta Felip, head of the Medical Oncology Department at Vall d'Hebron University Hospital, head of the Thoracic Tumours Group, and co-director of the Clinical Research Program at Vall d'Hebron Institute of Oncology (VHIO), presented the results of the secondary analysis of the phase 3 MARIPOSA clinical trial on the opening day of the 2024 ASCO Annual Meeting.
This analysis reinforces the clinical benefits for patients with non-small cell lung cancer with EGFR mutations compared to the current standard treatment, even in patients with a very poor prognosis. The EGFR gene mutation is found in approximately 15% of patients with non-small cell lung cancer, being one of the most common oncogenic mutations in this type of cancer. "In these cases, if the tumour is advanced or metastatic, new therapeutic strategies are needed, especially in early lines of treatment," explained Dr Felip.
A third-generation oral EGFR inhibitor is the standard treatment for these patients. However, the disease will eventually progress because the tumour develops molecular alterations that make it resistant to osime.
